Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria
- 9 December 2003
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 100 (25) , 15083-15088
- https://doi.org/10.1073/pnas.2036598100
Abstract
The low level of oxygenation within tumors is a major cause of radiation treatment failures. We theorized that anaerobic bacteria that can selectively destroy the hypoxic regions of tumors would enhance the effects of radiation. To test this hypothesis, we used spores of Clostridium novyi-NT to treat transplanted tumors in mice. The bacteria were found to markedly improve the efficacy of radiotherapy in several of the mouse models tested. Enhancement was noted with external beam radiation derived from a Cs-137 source, systemic radioimmunotherapy with an I-131-conjugated monoclonal antibody, and a previously undescribed form of experimental brachytherapy using plaques loaded with I-125 seeds. C. novyi-NT spores added little toxicity to the radiotherapeutic regimens, and the combination resulted in long-term remissions in a significant fraction of animals.Keywords
This publication has 17 references indexed in Scilit:
- Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.2003
- Tumor Response to Radiotherapy Regulated by Endothelial Cell ApoptosisScience, 2003
- Colonic tumor CEA, CSAp and MUC-1 expression following radioimmunotherapy or chemotherapy.Tumor Biology, 2003
- Impact of Tumor Hypoxia and Anemia on Radiation Therapy OutcomesThe Oncologist, 2002
- Limitations of conventional doses of chemoradiation for unresectable biliary cancerInternational Journal of Radiation Oncology*Biology*Physics, 2002
- External-beam radiotherapy in the management of liver metastasesSeminars in Oncology, 2002
- Radioimmunotherapy of small-volume disease of metastatic colorectal cancerCancer, 2002
- Can engineered bacteria help control cancer?Proceedings of the National Academy of Sciences, 2001
- Combination bacteriolytic therapy for the treatment of experimental tumorsProceedings of the National Academy of Sciences, 2001
- A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free mediumIn Vitro Cellular & Developmental Biology, 1989